CTLA4 and melanoma: In March 2011, immune checkpoint inhibition was introduced as a new cancer therapeutic paradigm with FDA approval of the anti-cytotoxic T lymphocyte-associated antigen-4(CTLA-4) antibody ipilimumab for the treatment of advanced melanoma.